Closing the Information Gap on International Surrogacy
By Elayne Clift,
Women's Media Center
| 07. 16. 2014
[Quotes CGS's Marcy Darnovsky]
Untitled Document
Beth G. had eight miscarriages before she and her partner considered in vitro fertilization (IVF). The couple also discussed adoption, but they ultimately opted for a surrogate in India. Beth and her partner visited Mumbai before signing on and felt that the gestational mothers in their agency were well cared for and decently compensated. But what did they really know about the practice of cross-border surrogacy?
In order to help close the information gap that exists around both cross-border surrogacy and commercial egg retrieval (from egg “donors”), the MacArthur Foundation recently awarded the women’s health advocacy group Our Bodies Ourselves (OBOS) and the Center for Genetics and Society (CGS) a two-year, $200,000 grant to support the collaborating organizations’ joint efforts to bring a human rights and social justice perspective to these two assisted reproductive technologies (ART) and to the rapidly growing industry they have spawned. Most countries prohibit commercial surrogacy, but in nations where it is allowed, policies vary greatly. India is the most popular destination, but prospective parents seek paid surrogates in a number of countries, including...
Related Articles
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
By Siddhi Mahatole and Mariam E. Sunny, Reuters | 06.13.2025
Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' (REGN.O), opens new tab offer for the DNA-testing company in a bankruptcy auction.
Last month, Regeneron agreed to...